Contrarian Corpus
short seller research note initial thesis
2023-04-19 · 8 pages

Freedom Holding Corp FRHC

FRHC funnels 85% of revenue through a CEO-owned Belize affiliate (FFIN) sourcing Russian flows — an FTX/Alameda structure that should trigger restatement, sanctions violations, and Nasdaq delisting.

N 4 Narrative
V 2 Visual
C 1 Craft
Source URL unavailable

Thesis

Citron argues Freedom Holding Corp (FRHC) is the Belize/Russian analogue of FTX/Alameda: CEO Timur Turlov, who owns ~75% of FRHC and was personally sanctioned by Ukraine in October 2022 for supporting Russia, separately controls FFIN Brokerage Services in Belize, an unaudited related party that channels the majority of FRHC's revenue (85%) and margin lending (95%), much of it sourced from Russian customers. In December 2022 the PCAOB fined and barred FRHC's auditors for failing to interrogate why retail orders were routed through the CEO's Belize entity before reaching Freedom. If FFIN is properly consolidated as a variable interest entity, Freedom would have to restate financials and would immediately be in violation of Russian war sanctions, warranting SEC, Nasdaq and regulator action — and likely delisting.

SCQA

Situation

Freedom Holding Corp is a Nasdaq-listed Kazakh-headquartered broker-dealer led by 35-year-old CEO Timur Turlov, who owns roughly 75% of the equity and built the firm around retail trading flows from the former Soviet bloc.

Complication

85% of FRHC's revenue and 95% of margin lending pass through FFIN Brokerage, a Belize entity solely owned by Turlov that sources flow from Russia; Ukraine sanctioned him, and the PCAOB barred FRHC's auditors for ignoring the related-party risk.

Resolution

The SEC, Nasdaq and PCAOB should force FRHC to consolidate FFIN as a variable interest entity, restate financials, and delist the security if the consolidation confirms violations of Russian war sanctions.

Reward

No explicit price target, but the implied downside is severe: a forced restatement plus sanctions-driven Nasdaq delisting would collapse FRHC's equity value, mirroring the FTX outcome Citron invokes throughout the report.

The three reasons

  1. 1

    FFIN Brokerage is a CEO-controlled Belize affiliate funneling Russian flows — an FTX/Alameda parallel

  2. 2

    PCAOB fined and barred FRHC's auditors in Dec 2022 for failing to scrutinize the FFIN relationship

  3. 3

    CEO Turlov was personally sanctioned by Ukraine for supporting the Russian Federation

Primary demands

  • SEC and NASDAQ should investigate FRHC for sanctions violations and related-party manipulation
  • Treat FFIN Brokerage (Belize) as a consolidated subsidiary, forcing financial restatement
  • Delist FRHC if confirmed in violation of Russian war sanctions

KPIs cited

Share of FRHC revenue from FFIN
85% of revenues are generated through the CEO-controlled Belize affiliate
Share of margin lending from FFIN
95% of margin lending runs through FFIN Brokerage
CEO ownership of FRHC
Timur Turlov owns ~75% of Freedom Holding Corp stock
PCAOB sanction date
Auditors fined and barred under PCAOB Release 105-2022-038, December 20, 2022
Ukraine sanctions list inclusion
Turlov added October 19, 2022; Freedom Finance Ukraine license suspended for 5 years on Nov 9, 2022

Pattern membership

Where this document fits across the library's 12 rhetorical / structural patterns.

Precedents cited

  • FTX / Alameda Research (related-party concealment)
  • Forbes 30 Under 30 'curse'

Notable slides (4)

Notes

Prose-style short report (8 pages, ~5 pages of body + disclaimer) rather than a deck. Core rhetorical move is the explicit FTX/Alameda analogy — Citron lists 7 parallels between FRHC and FTX on page 6 (wunderkind CEO, related-party obfuscation, effective-altruism posture, weak board, US brokerage acquisition attempt, tax-haven domicile). Uses Turlov's own 'technical error' / 'mechanical' quotes about the Ukraine sanctions to set up a contradiction. PCAOB enforcement action against auditors Reams/Keyes (Release 105-2022-038) is the strongest evidentiary anchor. No explicit price target or short-position disclosure beyond standard Citron boilerplate. No author signature beyond the Citron Research brand.